“…It can occur at any place where mesothelial cells de-differentiate from mesenchymal cells, including the pericardium, peritoneum, tunica vaginalis of the ovary and testis, although both pleurae (visceral and parietal pleura) are the most common affected structures. 8,9 The incidence of MPM in in Japan and Europe are projected to peak in 2025 and 2020 respectively, while the incidence in the USA has remained stable at 3000 deaths per year since peaking in 2004. 10 Surgical resection is the best therapeutic approach in early stages MPM (I, II and selected N0 stage III) without distant diffusion as well as radiotherapy as complementary or symptomatic treatment.…”